Aventis Pharma today said its net profit surged over fourfold to Rs 104.9 crore in the fourth quarter ended December 31, 2010, over the same period last fiscal.
The company had posted a net profit of Rs 26 crore for the same period previous fiscal, Aventis Pharma said in a filing the Bombay Stock Exchange (BSE).
Total income of the company rose to Rs 307.2 crore for Q4 2010, compared to Rs 258.7 crore in the same period previous fiscal.
During the quarter, the company sold its entire share holding of 49% of paid up share capital of the joint venture company Chiron Behring Vaccines (CBVPL) to Novartis Pharma AG for a consideration of Rs 100.75 crore.
The company's board recommended a final dividend of Rs 23 per share of Rs 10 for the year ended December 31, 2010.
The board also approved a special one time dividend of Rs 28 per share of Rs 10, arising from the profit of the sale of the company's shareholding in CBVPL.
For the year, the company posted a net profit of Rs 230.7 crore, compared to Rs 157.4 crore in the last fiscal, 2009.
Shares of Aventis Pharma today closed at Rs 1,846.95 on the BSE, up 1.20% from its previous close.
